A study in human patients with coronary artery disease identified the mir-216b as a biomarker for recurrent myocardial infarction risk, where it was downregulated in whole blood samples from patients with recurrent MI compared to those without, with this differential expression meeting a false discovery rate correction threshold of less than 0.1 [Onuoha et al. DOI:10.1111/cts.13307]. The analysis found no significant differential expression for this miRNA in plasma samples, and the research concluded that whole blood is the preferred sample source for miRNA profiling related to thrombotic risk prognosis.